Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 ng » 100 ng (Expand Search), 10 mg (Expand Search), 10 nm (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
Showing 121 - 140 results of 43,392 for search '(((( 50 a decrease ) OR ( 5 ((ng decrease) OR (we decrease)) ))) OR ( 10 ng decrease ))', query time: 0.71s Refine Results
  1. 121
    <i>Pfmrp1</i> gene SNPs data during the study period.

    <i>Pfmrp1</i> gene SNPs data during the study period. by Winnie Okore (14139712)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 122
    Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period.

    Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period. by Winnie Okore (14139712)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 123
    <i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials.

    <i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 124
    Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19.

    Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

    Published 2020
    Save to List
    Saved in:
  5. 125
    Acquisition of Mutant scFv With a Higher Affinity against Wild-type, Beta and Delta SARS-CoV-2 using a HEK 293T Antibody Surface Display Library.

    Acquisition of Mutant scFv With a Higher Affinity against Wild-type, Beta and Delta SARS-CoV-2 using a HEK 293T Antibody Surface Display Library. by Ye Yang (297214)

    Published 2023
    Save to List
    Saved in:
  6. 126
    Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19.

    Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

    Published 2020
    Save to List
    Saved in:
  7. 127
    Klf5 expression is down-regulated in the ruptured human and experimental AAA.

    Klf5 expression is down-regulated in the ruptured human and experimental AAA. by Dong Ma (584680)

    Published 2020
    Save to List
    Saved in:
  8. 128
    Source data for Fig 1.

    Source data for Fig 1. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  9. 129
    Source data for Fig 2.

    Source data for Fig 2. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  10. 130
    Source data for Fig 3.

    Source data for Fig 3. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  11. 131
    Demographics and baseline characteristics of the safety population.

    Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  12. 132
    Grading of stool consistency and diarrhea severity.

    Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  13. 133
    Secondary efficacy endpoints for the modified intent-to-treat population.

    Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  14. 134
    Source data for S1 and S2 Figs.

    Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  15. 135
    Consolidated Standards for Reporting of Trials flow diagram.

    Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  16. 136
    Diarrheal disease severity by treatment group for the modified intent-to-treat population.

    Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  17. 137
    iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model.

    iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  18. 138
    Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population.

    Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  19. 139
    iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model.

    iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  20. 140
    Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population.

    Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

    Published 2021
    Subjects:
    Save to List
    Saved in:

Search Tools: